CBDM.T®, The Market and Business Intelligence Company Reviews The Dry
Eye Disease Treatment Market
According to CBDM.T®, the market and business intelligence company, the Dry Eye market is
huge and growing valued at 1.7 billion USD in 2009 with an annual growth of about 10 to 11%.
The Dry Eye market could account for more than 2.4 billion USD by 2014.
Paris, France (PRWEB) April 28, 2010 -- Dry eye disease (DED) is one of the most frequently encountered ocular
morbidities. 25 % percent of patients who visit ophthalmic clinics report symptoms of dry eye, making it a
growing public health problem and one of the most common conditions seen by eye care practitioners. Dry eye
affects an estimated 20 to 30 million people in the United States and is one of the most common reasons that
people visit their eye doctor. Dry eye’s prevalence estimation is very variable but we could estimate that more
than 70 million people are or will be affected by dry ocular symptoms. According to CBDM.T, Dry Eye
represents one of the fastest growing pharmaceutical product categories in the ophthalmology market at over 10%
growth per annum to 2014. The market potential for dry eye drugs is projected to reach 1 billion USD by 2015.
The first line of treatment is usually eye drops that act as artificial tears and give some temporary relief. Restasis
(cyclosporine A ophthalmic emulsion) 0.05% is the first approved prescription product in the United States for the
treatment of dry eye disease. Restasis (Allergan) sales were 270 million USD in 2006s to 444 million USD by
2008.
In 2008, more than 15 products were under development from discovery, preclinical, clinical phase 1, clinical
phase 2 (5 products) to clinical phase 3 with 8 products. The leading companies in this market are Novartis, Alcon
(acquired by Novartis), Bausch & Lomb, Vistakon (J&J), Allergan, Pfizer and AMO (Abbott Medical Optics Inc).
According to CBDM.T®, the market and business intelligence company, the Dry Eye Disease (DED) market is
huge and growing valued at 1